MX2018009097A - Nuevo derivado de imidazol que tiene actividad inhibidora de jnk y uso del mismo. - Google Patents

Nuevo derivado de imidazol que tiene actividad inhibidora de jnk y uso del mismo.

Info

Publication number
MX2018009097A
MX2018009097A MX2018009097A MX2018009097A MX2018009097A MX 2018009097 A MX2018009097 A MX 2018009097A MX 2018009097 A MX2018009097 A MX 2018009097A MX 2018009097 A MX2018009097 A MX 2018009097A MX 2018009097 A MX2018009097 A MX 2018009097A
Authority
MX
Mexico
Prior art keywords
inhibitory activity
imidazole derivative
novel imidazole
jnk
jnk inhibitory
Prior art date
Application number
MX2018009097A
Other languages
English (en)
Inventor
Hah Jung-Mi
I Yang Song
Hun Lee Jung
Original Assignee
Samjin Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samjin Pharm Co Ltd filed Critical Samjin Pharm Co Ltd
Publication of MX2018009097A publication Critical patent/MX2018009097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

La presente invención se refiere a un nuevo derivado de imidazol que tiene una actividad inhibidora de quinasa C-Jun N-terminal (JNK) y a un uso del mismo. Un nuevo derivado de imidazol o una sal del mismo farmacéuticamente aceptable de acuerdo con la presente invención, presenta una excelente actividad inhibidora contra la quinasa C-Jun N-terminal (JNK), y por tanto se espera que sea posible una estrategia y un tratamiento dirigido más esenciales en la prevención o el tratamiento de enfermedades degenerativas del sistema nervioso cerebral.
MX2018009097A 2016-01-29 2017-01-25 Nuevo derivado de imidazol que tiene actividad inhibidora de jnk y uso del mismo. MX2018009097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160011683 2016-01-29
PCT/KR2017/000860 WO2017131425A1 (ko) 2016-01-29 2017-01-25 Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2018009097A true MX2018009097A (es) 2019-03-06

Family

ID=59398384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009097A MX2018009097A (es) 2016-01-29 2017-01-25 Nuevo derivado de imidazol que tiene actividad inhibidora de jnk y uso del mismo.

Country Status (11)

Country Link
US (1) US10301291B2 (es)
EP (1) EP3409668B1 (es)
JP (1) JP6626981B2 (es)
KR (1) KR101894096B1 (es)
CN (1) CN108699041B (es)
BR (1) BR112018015482A2 (es)
CA (1) CA3013022C (es)
ES (1) ES2830743T3 (es)
MX (1) MX2018009097A (es)
RU (1) RU2702749C1 (es)
WO (1) WO2017131425A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020022787A1 (ko) * 2018-07-24 2020-01-30 삼진제약주식회사 Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물
KR102514245B1 (ko) * 2019-12-03 2023-03-29 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 피라졸 유도체 및 이의 용도
KR102642716B1 (ko) * 2021-08-18 2024-03-04 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
KR100337189B1 (ko) 1999-09-30 2002-05-18 복성해 인간세포의 인산화 효소 ｊｎｋ의 활성 조절인자로 작용하는 마우스의 ｓｋｉｐ 단백질 및 ｓｋｉｐ 유전자
US6410726B1 (en) * 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
US6958340B2 (en) * 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
TW200610762A (en) * 2004-06-10 2006-04-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
BRPI0608513A2 (pt) * 2005-03-15 2010-01-05 Irm Llc compostos e composições como inibidores da proteìna quinase
KR101123071B1 (ko) * 2009-10-23 2012-03-05 한국과학기술연구원 신규 이미다졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 흑색종의 예방 및 치료용 약학적 조성물
KR101469127B1 (ko) * 2013-03-11 2014-12-04 한양대학교 에리카산학협력단 신규 벤즈이미다졸 유도체, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
CA3013022C (en) 2020-09-22
EP3409668A4 (en) 2019-07-31
EP3409668B1 (en) 2020-10-21
KR20170091516A (ko) 2017-08-09
CN108699041A (zh) 2018-10-23
WO2017131425A1 (ko) 2017-08-03
CN108699041B (zh) 2021-03-26
US20190031645A1 (en) 2019-01-31
JP2019508396A (ja) 2019-03-28
BR112018015482A2 (pt) 2018-12-18
RU2702749C1 (ru) 2019-10-11
CA3013022A1 (en) 2017-08-03
EP3409668A1 (en) 2018-12-05
US10301291B2 (en) 2019-05-28
ES2830743T3 (es) 2021-06-04
JP6626981B2 (ja) 2019-12-25
KR101894096B1 (ko) 2018-09-05

Similar Documents

Publication Publication Date Title
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
NZ732394A (en) Parg inhibitory compounds
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
MX2018009097A (es) Nuevo derivado de imidazol que tiene actividad inhibidora de jnk y uso del mismo.
WO2018218197A3 (en) ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE
PH12019500198A1 (en) Compounds and compositions and uses thereof
WO2018151562A3 (ko) Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MY192305A (en) Bipyrazole derivatives as jak inhibitors